Latest News

Drug combo indicated for bacterial pneumonia


The Food and Drug Administration has approved expanding the indication for the drug combination of ceftazidime and avibactam (Avycaz) to include hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adults.

Specifically, the approved indication is for infections caused by certain Gram-negative bacteria – some of which are increasingly resistant to available antibiotics – including, Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae.

There have not been new treatment options for HABP/VABP caused by Gram-negative bacteria in more than 15 years, according to Allergan, the drug’s manufacturer.

FDA icon
The approval of the expanded indication was based on data from the phase 3, multinational, double-blind REPROVE trial. The study showed that ceftazidime/avibactam was noninferior to meropenem with respect to 28-day all-cause mortality.

This is the third approved indication for ceftazidime/avibactam; the other two indications are for complicated intra-abdominal infections (in combination with metronidazole) and for complicated urinary tract infections.

Next Article:

   Comments ()